|

Filgotinib Clinical Trials

4 actively recruiting trials

No change since June 2026

Also known as: GLPG0634, GS-6034, Jyseleca

Pipeline

Phase 3: 2Phase 4: 2

Top Sponsors

  • Alfasigma S.p.A.2
  • Universita di Verona1
  • R.Bos1

Indications

  • Arthritis4
  • Rheumatoid Arthritis2
  • Polyarticular Course Juvenile Idiopathic Arthritis1
  • Juvenile Idiopathic Arthritis (JIA)1

Other4 trials

Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH)
Phase 4
Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)
Phase 4
OLE Study With Filgotinib in JIA
Phase 3
Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.